Patents by Inventor Thomas W. Hodge, III

Thomas W. Hodge, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V
    Patent number: 9919034
    Abstract: Viral infections in mammals can be treated and prophylactically prevented by systemic administration of ranpirnase and three other ribonucleases that are highly homologous with it and that have activities that are highly similar to it. Experimental results against rabies, Middle East Respiratory Syndrome Coronavirus (“MERS-CoV”), influenza, Ebola virus, Chikungunya virus, Venezuelan equine encephalitis, canine parvovirus, adenovirus-2, respiratory syncytial virus, rhinovirus-14, and vaccinia are disclosed.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: March 20, 2018
    Assignee: TAMIR BIOTECHNOLOGY, INC.
    Inventor: Thomas W. Hodge, III
  • METHODS OF TREATING ZIKA VIRUS, MERS-COV, CHIKUNGUNYA, VENEZUELAN EQUINE ENCEPHALITUS, AND RHINOVIRUS IN MAMMALIAN PATIENTS
    Publication number: 20170157219
    Abstract: Viral infections in mammals can be treated and prophylactically prevented by systemic administration of ranpirnase and three other ribonucleases that are highly homologous with it and that have activities that are highly similar to it. Experimental results against Zika virus, Middle East Respiratory Syndrome Coronavirus (“MERS-CoV”), Chikungunya virus, Venezuelan equine encephalitis, and rhinovirus-14 are disclosed.
    Type: Application
    Filed: February 9, 2017
    Publication date: June 8, 2017
    Applicant: Tamir Biotechnology, Inc.
    Inventor: Thomas W. Hodge, III
  • METHODS OF TREATING VIRAL INFECTIONS, PARTICULARLY RABIES, MERS-COV, INFLUENZA, EBOLA, CHIKUNGUNYA, VENEZUELAN EQUINE ENCEPHALITUS, CANINE PARVOVIRUS, ADENOVIRUS, RESPIRATORY SYNCYTIAL VIRUS, RHINOVIRUS, AND POXVIRUS IN MAMMALIAN PATIENTS
    Publication number: 20150376584
    Abstract: Viral infections in mammals can be treated and prophylactically prevented by systemic administration of ranpirnase and three other ribonucleases that are highly homologous with it and that have activities that are highly similar to it. Experimental results against rabies, Middle East Respiratory Syndrome Coronavirus (“MERS-CoV”), influenza, Ebola virus, Chikungunya virus, Venezuelan equine encephalitis, canine parvovirus, adenovirus-2, respiratory syncytial virus, rhinovirus-14, and vaccinia are disclosed.
    Type: Application
    Filed: June 10, 2015
    Publication date: December 31, 2015
    Applicant: TAMIR BIOTECHNOLOGY, INC.
    Inventor: Thomas W. Hodge, III